Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals
An AML drug picked up by Daiichi Sankyo in its Ambit buyout has outshone chemotherapy in a late-stage trial, setting up the Japanese drugmaker to file for worldwide approvals.
The drug, called quizartinib, was tested in a Phase III study against relapsed or refractory acute myeloid leukemia (blood and bone marrow cancer) — particularly in patients who have the FLT3-ITD mutation. This dangerous (but fairly common) mutation affects one in four AML patients, giving them a worse overall prognosis, including more relapses and an increased risk of death following relapse. There are no approved treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.